CA2682231A1 - Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors - Google Patents
Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors Download PDFInfo
- Publication number
- CA2682231A1 CA2682231A1 CA002682231A CA2682231A CA2682231A1 CA 2682231 A1 CA2682231 A1 CA 2682231A1 CA 002682231 A CA002682231 A CA 002682231A CA 2682231 A CA2682231 A CA 2682231A CA 2682231 A1 CA2682231 A1 CA 2682231A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- mmol
- compound
- formula
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 title description 3
- 150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 177
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims abstract description 16
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims abstract description 16
- 230000001404 mediated effect Effects 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 237
- 238000002360 preparation method Methods 0.000 claims description 184
- 238000000034 method Methods 0.000 claims description 74
- -1 C(O)NHMe Chemical compound 0.000 claims description 55
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 48
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 25
- 229910052731 fluorine Inorganic materials 0.000 claims description 23
- 229910052801 chlorine Inorganic materials 0.000 claims description 17
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 15
- 125000004429 atom Chemical group 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 13
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 9
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 9
- 229910052763 palladium Inorganic materials 0.000 claims description 9
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 claims description 8
- 206010016654 Fibrosis Diseases 0.000 claims description 8
- 125000003386 piperidinyl group Chemical group 0.000 claims description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 7
- 230000008878 coupling Effects 0.000 claims description 7
- 238000010168 coupling process Methods 0.000 claims description 7
- 238000005859 coupling reaction Methods 0.000 claims description 7
- 230000004761 fibrosis Effects 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 5
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 2
- 230000001335 demethylating effect Effects 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 18
- 239000003112 inhibitor Substances 0.000 abstract description 16
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 10
- 102000005962 receptors Human genes 0.000 abstract description 3
- 108020003175 receptors Proteins 0.000 abstract description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 322
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 275
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 267
- 238000006243 chemical reaction Methods 0.000 description 235
- 239000000203 mixture Substances 0.000 description 133
- 239000007787 solid Substances 0.000 description 128
- 201000006417 multiple sclerosis Diseases 0.000 description 124
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 106
- 235000019439 ethyl acetate Nutrition 0.000 description 104
- 239000000243 solution Substances 0.000 description 103
- 239000000047 product Substances 0.000 description 102
- 238000007792 addition Methods 0.000 description 90
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 77
- 239000011541 reaction mixture Substances 0.000 description 76
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 74
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 66
- 229910001868 water Inorganic materials 0.000 description 59
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 54
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 53
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 48
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 44
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 44
- 239000010410 layer Substances 0.000 description 43
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 43
- 229910052938 sodium sulfate Inorganic materials 0.000 description 41
- 235000011152 sodium sulphate Nutrition 0.000 description 41
- 238000010992 reflux Methods 0.000 description 40
- 239000007832 Na2SO4 Substances 0.000 description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 239000012044 organic layer Substances 0.000 description 39
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 36
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 35
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 34
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 32
- 238000003818 flash chromatography Methods 0.000 description 32
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 32
- 238000003756 stirring Methods 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 29
- 239000003921 oil Substances 0.000 description 29
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 28
- 229920006395 saturated elastomer Polymers 0.000 description 28
- 239000012074 organic phase Substances 0.000 description 24
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 23
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
- 229910052786 argon Inorganic materials 0.000 description 22
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 22
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 22
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 235000011114 ammonium hydroxide Nutrition 0.000 description 21
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 18
- 229910000024 caesium carbonate Inorganic materials 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 235000019341 magnesium sulphate Nutrition 0.000 description 17
- 238000010898 silica gel chromatography Methods 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 15
- HBBYDTFNQNAFJA-UHFFFAOYSA-N 4-(2-methoxyethoxy)pyridin-2-amine Chemical compound COCCOC1=CC=NC(N)=C1 HBBYDTFNQNAFJA-UHFFFAOYSA-N 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 14
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 14
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 14
- 101150041968 CDC13 gene Proteins 0.000 description 13
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 13
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical group C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 13
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 238000001816 cooling Methods 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 description 12
- 238000001665 trituration Methods 0.000 description 12
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 11
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 11
- 239000008367 deionised water Substances 0.000 description 11
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 10
- 229910052794 bromium Inorganic materials 0.000 description 10
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 10
- 239000012141 concentrate Substances 0.000 description 10
- 235000008504 concentrate Nutrition 0.000 description 10
- 229910052740 iodine Inorganic materials 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 10
- NWPHMULLPITJJY-UHFFFAOYSA-N 8-bromo-5-fluoroquinoline-2-carboxylic acid Chemical compound FC1=CC=C(Br)C2=NC(C(=O)O)=CC=C21 NWPHMULLPITJJY-UHFFFAOYSA-N 0.000 description 9
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 9
- 229910003827 NRaRb Inorganic materials 0.000 description 9
- 229910021641 deionized water Inorganic materials 0.000 description 9
- 239000012452 mother liquor Substances 0.000 description 9
- 239000012299 nitrogen atmosphere Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- UDVPQRRWUGKGQY-XQHVRGAUSA-N (e)-but-2-enal Chemical compound C\C=C\C=O.C\C=C\C=O UDVPQRRWUGKGQY-XQHVRGAUSA-N 0.000 description 8
- KDBADDXDBJFAAO-UHFFFAOYSA-N 7-(2-methoxyethoxy)imidazo[1,2-a]pyridine Chemical compound C1=C(OCCOC)C=CN2C=CN=C21 KDBADDXDBJFAAO-UHFFFAOYSA-N 0.000 description 8
- MJWZFQJNGFPWGE-UHFFFAOYSA-N 8-bromo-5-fluoroquinoline-2-carbaldehyde Chemical compound O=CC1=CC=C2C(F)=CC=C(Br)C2=N1 MJWZFQJNGFPWGE-UHFFFAOYSA-N 0.000 description 8
- CLFPSUQMEIZXHS-UHFFFAOYSA-N 8-bromo-6-fluoroquinoline-2-carboxylic acid Chemical compound C1=C(F)C=C(Br)C2=NC(C(=O)O)=CC=C21 CLFPSUQMEIZXHS-UHFFFAOYSA-N 0.000 description 8
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
- VBGAGHHSRWJFCP-UHFFFAOYSA-N [2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl] trifluoromethanesulfonate Chemical compound C1=CC=C(OS(=O)(=O)C(F)(F)F)C2=NC(C=3N4C=CC(=CC4=NC=3)OCCOC)=CC=C21 VBGAGHHSRWJFCP-UHFFFAOYSA-N 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- SJFNDMHZXCUXSA-UHFFFAOYSA-M methoxymethyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(COC)C1=CC=CC=C1 SJFNDMHZXCUXSA-UHFFFAOYSA-M 0.000 description 8
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 8
- FBPINGSGHKXIQA-UHFFFAOYSA-N 2-amino-3-(2-carboxyethylsulfanyl)propanoic acid Chemical compound OC(=O)C(N)CSCCC(O)=O FBPINGSGHKXIQA-UHFFFAOYSA-N 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 7
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 7
- SGDSAOOGSGZQQW-UHFFFAOYSA-N benzyl n-(4-methylpiperidin-4-yl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1(C)CCNCC1 SGDSAOOGSGZQQW-UHFFFAOYSA-N 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 102000027495 nuclear receptors type III Human genes 0.000 description 7
- 108091008732 nuclear receptors type III Proteins 0.000 description 7
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 7
- SRJOCJYGOFTFLH-UHFFFAOYSA-M piperidine-4-carboxylate Chemical compound [O-]C(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-M 0.000 description 7
- 229910001961 silver nitrate Inorganic materials 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000010792 warming Methods 0.000 description 7
- KQVLBDVPZZJAJD-UHFFFAOYSA-N (8-bromo-5-fluoroquinolin-2-yl)methanol Chemical compound FC1=CC=C(Br)C2=NC(CO)=CC=C21 KQVLBDVPZZJAJD-UHFFFAOYSA-N 0.000 description 6
- MTDOAXRREVUUAU-UHFFFAOYSA-N 2-chloro-4-(2-methoxyethoxy)pyridine Chemical compound COCCOC1=CC=NC(Cl)=C1 MTDOAXRREVUUAU-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- DWPWWTIOOLQURY-NEPJUHHUSA-N benzyl n-[(3r,4s)-3-fluoropiperidin-4-yl]carbamate Chemical compound F[C@@H]1CNCC[C@@H]1NC(=O)OCC1=CC=CC=C1 DWPWWTIOOLQURY-NEPJUHHUSA-N 0.000 description 6
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 6
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 238000000638 solvent extraction Methods 0.000 description 6
- 238000010626 work up procedure Methods 0.000 description 6
- LIEPVGBDUYKPLC-UHFFFAOYSA-N 2-chloro-4-nitropyridine Chemical compound [O-][N+](=O)C1=CC=NC(Cl)=C1 LIEPVGBDUYKPLC-UHFFFAOYSA-N 0.000 description 5
- WNCMKCYNUDBQQO-UHFFFAOYSA-N 8-bromo-2-(dibromomethyl)-5-fluoroquinoline Chemical compound BrC(Br)C1=CC=C2C(F)=CC=C(Br)C2=N1 WNCMKCYNUDBQQO-UHFFFAOYSA-N 0.000 description 5
- LRBSJYHYOPQSOG-UHFFFAOYSA-N 8-bromo-2-(dibromomethyl)-6-fluoroquinoline Chemical compound N1=C(C(Br)Br)C=CC2=CC(F)=CC(Br)=C21 LRBSJYHYOPQSOG-UHFFFAOYSA-N 0.000 description 5
- SKYJNBNYCRKOPC-UHFFFAOYSA-N 8-bromo-5-fluoro-2-methylquinoline Chemical compound FC1=CC=C(Br)C2=NC(C)=CC=C21 SKYJNBNYCRKOPC-UHFFFAOYSA-N 0.000 description 5
- IWVKLZLPGJIBHU-UHFFFAOYSA-N 8-bromo-6-fluoroquinoline-2-carbaldehyde Chemical compound N1=C(C=O)C=CC2=CC(F)=CC(Br)=C21 IWVKLZLPGJIBHU-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 5
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- VDQVEACBQKUUSU-UHFFFAOYSA-M disodium;sulfanide Chemical compound [Na+].[Na+].[SH-] VDQVEACBQKUUSU-UHFFFAOYSA-M 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 229910052979 sodium sulfide Inorganic materials 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 5
- MYFJWPVRMORXRD-UHFFFAOYSA-N (8-bromo-6-fluoroquinolin-2-yl)methanol Chemical compound C1=C(F)C=C(Br)C2=NC(CO)=CC=C21 MYFJWPVRMORXRD-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- JEHWQJWDPOQIMX-UHFFFAOYSA-N 8-bromo-5-fluoro-2-(2-methoxyethenyl)quinoline Chemical compound FC1=CC=C(Br)C2=NC(C=COC)=CC=C21 JEHWQJWDPOQIMX-UHFFFAOYSA-N 0.000 description 4
- ZCACBJCEFFPJFB-UHFFFAOYSA-N 8-bromo-5-fluoro-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound FC1=CC=C(Br)C2=NC(C=3N4C=CC(=CC4=NC=3)OCCOC)=CC=C21 ZCACBJCEFFPJFB-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 206010039710 Scleroderma Diseases 0.000 description 4
- 239000000010 aprotic solvent Substances 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- ZTWNQHNXEOMECF-UHFFFAOYSA-N ethyl 8-bromo-6-fluoroquinoline-2-carboxylate Chemical compound C1=C(F)C=C(Br)C2=NC(C(=O)OCC)=CC=C21 ZTWNQHNXEOMECF-UHFFFAOYSA-N 0.000 description 4
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- ZQZVWDXMUCTNRI-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 4-methylpiperidine-1,4-dicarboxylate Chemical compound CCOC(=O)C1(C)CCN(C(=O)OC(C)(C)C)CC1 ZQZVWDXMUCTNRI-UHFFFAOYSA-N 0.000 description 3
- MYHJCTUTPIKNAT-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl piperidine-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CC1 MYHJCTUTPIKNAT-UHFFFAOYSA-N 0.000 description 3
- PTZNCCIULVXFIJ-UHFFFAOYSA-N 1-o-tert-butyl 4-o-methyl piperidine-1,4-dicarboxylate Chemical compound COC(=O)C1CCN(C(=O)OC(C)(C)C)CC1 PTZNCCIULVXFIJ-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- DPABNLZUYUAAFA-UHFFFAOYSA-N 2,8-dibromoquinoline Chemical compound C1=CC=C(Br)C2=NC(Br)=CC=C21 DPABNLZUYUAAFA-UHFFFAOYSA-N 0.000 description 3
- YLMFXCIATJJKQL-UHFFFAOYSA-N 2-bromo-4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1Br YLMFXCIATJJKQL-UHFFFAOYSA-N 0.000 description 3
- FWTXFEKVHSFTDQ-UHFFFAOYSA-N 2-bromo-5-fluoroaniline Chemical compound NC1=CC(F)=CC=C1Br FWTXFEKVHSFTDQ-UHFFFAOYSA-N 0.000 description 3
- BAQKUNMKVAPWGU-UHFFFAOYSA-N 4-bromopyridin-2-amine Chemical compound NC1=CC(Br)=CC=N1 BAQKUNMKVAPWGU-UHFFFAOYSA-N 0.000 description 3
- OKBNEDPOUYRYNP-UHFFFAOYSA-N 4-methyl-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(C)(C(O)=O)CC1 OKBNEDPOUYRYNP-UHFFFAOYSA-N 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- ONNOGPKNEFHPCG-UHFFFAOYSA-N 7-pyridin-3-ylimidazo[1,2-a]pyridine Chemical compound C=1C2=NC=CN2C=CC=1C1=CC=CN=C1 ONNOGPKNEFHPCG-UHFFFAOYSA-N 0.000 description 3
- RIWYZQXJMWGAEN-UHFFFAOYSA-N 8-bromo-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound C1=CC=C(Br)C2=NC(C=3N4C=CC(=CC4=NC=3)OCCOC)=CC=C21 RIWYZQXJMWGAEN-UHFFFAOYSA-N 0.000 description 3
- HYNGTUOHHRSCMG-UHFFFAOYSA-N 8-bromo-6-fluoro-2-(2-methoxyethenyl)quinoline Chemical compound C1=C(F)C=C(Br)C2=NC(C=COC)=CC=C21 HYNGTUOHHRSCMG-UHFFFAOYSA-N 0.000 description 3
- MHOZAOOOCGCDQS-UHFFFAOYSA-N 8-bromo-6-fluoro-2-methylquinoline Chemical compound C1=C(F)C=C(Br)C2=NC(C)=CC=C21 MHOZAOOOCGCDQS-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 3
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 229960004217 benzyl alcohol Drugs 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- XAHXFLGTAKROPJ-UHFFFAOYSA-N ethyl 8-bromo-5-fluoroquinoline-2-carboxylate Chemical compound FC1=CC=C(Br)C2=NC(C(=O)OCC)=CC=C21 XAHXFLGTAKROPJ-UHFFFAOYSA-N 0.000 description 3
- RUJPPJYDHHAEEK-UHFFFAOYSA-N ethyl piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCNCC1 RUJPPJYDHHAEEK-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 108700014844 flt3 ligand Proteins 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 150000005232 imidazopyridines Chemical class 0.000 description 3
- ACEDOUSFSWERRO-UHFFFAOYSA-N n-methoxy-7-(2-methoxyethoxy)-n-methylimidazo[1,2-a]pyridine-3-carboxamide Chemical compound C1=C(OCCOC)C=CN2C(C(=O)N(C)OC)=CN=C21 ACEDOUSFSWERRO-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 description 3
- XBXHCBLBYQEYTI-UHFFFAOYSA-N piperidin-4-ylmethanol Chemical compound OCC1CCNCC1 XBXHCBLBYQEYTI-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- DVMUNQAGXAMHOR-UHFFFAOYSA-N tert-butyl 2,2-dimethylpiperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1(C)C DVMUNQAGXAMHOR-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 2
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 2
- QJPZQIWTHXZKRI-UHFFFAOYSA-N 1-(2-imidazo[1,2-a]pyridin-3-ylquinolin-8-yl)piperidin-4-ol Chemical compound C1CC(O)CCN1C1=CC=CC2=CC=C(C=3N4C=CC=CC4=NC=3)N=C12 QJPZQIWTHXZKRI-UHFFFAOYSA-N 0.000 description 2
- OCEXSCPSEDDTTN-UHFFFAOYSA-N 1-[2-(7-pyridin-2-ylimidazo[1,2-a]pyridin-3-yl)quinolin-8-yl]piperidin-4-amine Chemical compound C1CC(N)CCN1C1=CC=CC2=CC=C(C=3N4C=CC(=CC4=NC=3)C=3N=CC=CC=3)N=C12 OCEXSCPSEDDTTN-UHFFFAOYSA-N 0.000 description 2
- ZRYPCHJGPIGJQW-UHFFFAOYSA-N 1-[2-[7-(2-aminoethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]pyrrolidin-3-ol Chemical compound C=1N=C2C=C(OCCN)C=CN2C=1C(N=C12)=CC=C1C=CC=C2N1CCC(O)C1 ZRYPCHJGPIGJQW-UHFFFAOYSA-N 0.000 description 2
- CMCIOHMFAYJWAY-UHFFFAOYSA-N 1-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]piperidin-4-ol Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2N1CCC(O)CC1 CMCIOHMFAYJWAY-UHFFFAOYSA-N 0.000 description 2
- ZDVGWRZTMVVONN-UHFFFAOYSA-N 1-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]piperidin-4-one Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2N1CCC(=O)CC1 ZDVGWRZTMVVONN-UHFFFAOYSA-N 0.000 description 2
- VUYVXSSPDOWKFE-UHFFFAOYSA-N 1-benzyl-3,3-difluoropiperidine-4,4-diol Chemical compound C1C(F)(F)C(O)(O)CCN1CC1=CC=CC=C1 VUYVXSSPDOWKFE-UHFFFAOYSA-N 0.000 description 2
- QFLMSFRCLUMLIU-UHFFFAOYSA-N 2,8-dibromo-4-methylquinoline Chemical compound C1=CC=C2C(C)=CC(Br)=NC2=C1Br QFLMSFRCLUMLIU-UHFFFAOYSA-N 0.000 description 2
- MSLOSENVKADKAG-UHFFFAOYSA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-ol Chemical compound C1=CC=C(O)C2=NC(C=3N4C=CC(=CC4=NC=3)OCCOC)=CC=C21 MSLOSENVKADKAG-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- AOPBDRUWRLBSDB-UHFFFAOYSA-N 2-bromoaniline Chemical compound NC1=CC=CC=C1Br AOPBDRUWRLBSDB-UHFFFAOYSA-N 0.000 description 2
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 2
- NIEHWTGNWJVDEU-UHFFFAOYSA-N 2-chloro-8-phenylmethoxyquinoline Chemical compound C12=NC(Cl)=CC=C2C=CC=C1OCC1=CC=CC=C1 NIEHWTGNWJVDEU-UHFFFAOYSA-N 0.000 description 2
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- VZSPRDGYHFGDAY-UHFFFAOYSA-N 4-pyridin-3-ylpyridin-2-amine Chemical group C1=NC(N)=CC(C=2C=NC=CC=2)=C1 VZSPRDGYHFGDAY-UHFFFAOYSA-N 0.000 description 2
- VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical class C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 description 2
- OASOJRLJBDCVNU-UHFFFAOYSA-N 7-bromoimidazo[1,2-a]pyridine Chemical compound C1=C(Br)C=CN2C=CN=C21 OASOJRLJBDCVNU-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- HGJBIJWBYATVQY-UHFFFAOYSA-N 8-bromo-1h-quinolin-2-one Chemical compound C1=CC(=O)NC2=C1C=CC=C2Br HGJBIJWBYATVQY-UHFFFAOYSA-N 0.000 description 2
- ICPGCZYRDWYJST-UHFFFAOYSA-N 8-bromo-2-(7-pyridin-3-ylimidazo[1,2-a]pyridin-3-yl)quinoline Chemical compound N1=C2C(Br)=CC=CC2=CC=C1C(N1C=C2)=CN=C1C=C2C1=CC=CN=C1 ICPGCZYRDWYJST-UHFFFAOYSA-N 0.000 description 2
- QVSSXWTVSWLKSU-UHFFFAOYSA-N 8-bromo-2-methyl-6-(trifluoromethyl)quinoline Chemical compound C1=C(C(F)(F)F)C=C(Br)C2=NC(C)=CC=C21 QVSSXWTVSWLKSU-UHFFFAOYSA-N 0.000 description 2
- XYWCXYAAHSDBRF-UHFFFAOYSA-N 8-bromo-4-methyl-1h-quinolin-2-one Chemical compound C1=CC=C2C(C)=CC(=O)NC2=C1Br XYWCXYAAHSDBRF-UHFFFAOYSA-N 0.000 description 2
- ZGGQHOAJCRPWBX-UHFFFAOYSA-N 8-bromo-6-(trifluoromethyl)quinoline-2-carbaldehyde Chemical compound N1=C(C=O)C=CC2=CC(C(F)(F)F)=CC(Br)=C21 ZGGQHOAJCRPWBX-UHFFFAOYSA-N 0.000 description 2
- XGQUPMSDMCTRLT-UHFFFAOYSA-N 8-bromo-6-fluoro-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound C1=C(F)C=C(Br)C2=NC(C=3N4C=CC(=CC4=NC=3)OCCOC)=CC=C21 XGQUPMSDMCTRLT-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 2
- 229910015845 BBr3 Inorganic materials 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- GJWAPAVRQYYSTK-UHFFFAOYSA-N [(dimethyl-$l^{3}-silanyl)amino]-dimethylsilicon Chemical compound C[Si](C)N[Si](C)C GJWAPAVRQYYSTK-UHFFFAOYSA-N 0.000 description 2
- IITCIUNZYBJPJL-UHFFFAOYSA-N [4-amino-1-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]piperidin-4-yl]methanol Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2N1CCC(N)(CO)CC1 IITCIUNZYBJPJL-UHFFFAOYSA-N 0.000 description 2
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- DWPWWTIOOLQURY-VXGBXAGGSA-N benzyl n-[(3r,4r)-3-fluoropiperidin-4-yl]carbamate Chemical compound F[C@@H]1CNCC[C@H]1NC(=O)OCC1=CC=CC=C1 DWPWWTIOOLQURY-VXGBXAGGSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 2
- APEJMQOBVMLION-UHFFFAOYSA-N cinnamamide Chemical compound NC(=O)C=CC1=CC=CC=C1 APEJMQOBVMLION-UHFFFAOYSA-N 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- GUDMZGLFZNLYEY-UHFFFAOYSA-N cyclopropylmethanol Chemical compound OCC1CC1 GUDMZGLFZNLYEY-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- RNHIDHSYJSJPGV-UHFFFAOYSA-N n,n-dimethyl-2-[3-(8-pyrrolidin-1-ylquinolin-2-yl)imidazo[1,2-a]pyridin-7-yl]oxyethanamine Chemical compound C=1N=C2C=C(OCCN(C)C)C=CN2C=1C(N=C12)=CC=C1C=CC=C2N1CCCC1 RNHIDHSYJSJPGV-UHFFFAOYSA-N 0.000 description 2
- AVAWMINJNRAQFS-UHFFFAOYSA-N n,n-dimethylpyrrolidin-3-amine Chemical compound CN(C)C1CCNC1 AVAWMINJNRAQFS-UHFFFAOYSA-N 0.000 description 2
- XFBZFPHVMQLUKL-UHFFFAOYSA-N n-(2-bromophenyl)-3-oxobutanamide Chemical compound CC(=O)CC(=O)NC1=CC=CC=C1Br XFBZFPHVMQLUKL-UHFFFAOYSA-N 0.000 description 2
- VUTALNKXTAWHTC-UHFFFAOYSA-N n-benzyl-3,3-difluoropiperidin-4-amine Chemical compound FC1(F)CNCCC1NCC1=CC=CC=C1 VUTALNKXTAWHTC-UHFFFAOYSA-N 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 2
- UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 2
- NGXSWUFDCSEIOO-UHFFFAOYSA-N pyrrolidin-3-amine Chemical compound NC1CCNC1 NGXSWUFDCSEIOO-UHFFFAOYSA-N 0.000 description 2
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 description 2
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FPJKIRFAVMDZGK-UHFFFAOYSA-N tert-butyl 4-methyl-4-(phenylmethoxycarbonylamino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(C)NC(=O)OCC1=CC=CC=C1 FPJKIRFAVMDZGK-UHFFFAOYSA-N 0.000 description 2
- BHUKKFNQXNWGFW-UHFFFAOYSA-N tert-butyl n-(2-ethynyl-6-methoxyphenyl)carbamate Chemical compound COC1=CC=CC(C#C)=C1NC(=O)OC(C)(C)C BHUKKFNQXNWGFW-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000005490 tosylate group Chemical group 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JOMNTHCQHJPVAZ-RXMQYKEDSA-N (2r)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1 JOMNTHCQHJPVAZ-RXMQYKEDSA-N 0.000 description 1
- XMBSMMCPKFDGEO-ZETCQYMHSA-N (2s)-2-amino-5-[[amino-(2-methoxyethylamino)methylidene]amino]pentanoic acid Chemical compound COCCNC(=N)NCCC[C@H](N)C(O)=O XMBSMMCPKFDGEO-ZETCQYMHSA-N 0.000 description 1
- JOMNTHCQHJPVAZ-YFKPBYRVSA-N (2s)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1 JOMNTHCQHJPVAZ-YFKPBYRVSA-N 0.000 description 1
- XDPCNPCKDGQBAN-SCSAIBSYSA-N (3r)-oxolan-3-ol Chemical compound O[C@@H]1CCOC1 XDPCNPCKDGQBAN-SCSAIBSYSA-N 0.000 description 1
- INFPVGZBVOZWHB-MOPGFXCFSA-N (3r,4s)-3-fluoro-1-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]piperidin-4-amine Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2N1CC[C@H](N)[C@H](F)C1 INFPVGZBVOZWHB-MOPGFXCFSA-N 0.000 description 1
- XDPCNPCKDGQBAN-BYPYZUCNSA-N (3s)-oxolan-3-ol Chemical compound O[C@H]1CCOC1 XDPCNPCKDGQBAN-BYPYZUCNSA-N 0.000 description 1
- WOGITNXCNOTRLK-VOTSOKGWSA-N (e)-3-phenylprop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=CC=C1 WOGITNXCNOTRLK-VOTSOKGWSA-N 0.000 description 1
- FZGNQEIHILPJBW-ZHACJKMWSA-N (e)-n-(2-bromophenyl)-3-phenylprop-2-enamide Chemical compound BrC1=CC=CC=C1NC(=O)\C=C\C1=CC=CC=C1 FZGNQEIHILPJBW-ZHACJKMWSA-N 0.000 description 1
- XNJAYQHWXYJBBD-UHFFFAOYSA-N 1,4-difluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=CC=C1F XNJAYQHWXYJBBD-UHFFFAOYSA-N 0.000 description 1
- KPKNTUUIEVXMOH-UHFFFAOYSA-N 1,4-dioxa-8-azaspiro[4.5]decane Chemical compound O1CCOC11CCNCC1 KPKNTUUIEVXMOH-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- GMAWQTHVIIUMFA-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenoxy)acetyl]-n-(2-sulfanylethyl)piperidine-4-carboxamide Chemical compound C1CC(C(=O)NCCS)CCN1C(=O)COC1=CC=C(Cl)C=C1Cl GMAWQTHVIIUMFA-UHFFFAOYSA-N 0.000 description 1
- STQJFFXSEGCSLZ-UHFFFAOYSA-N 1-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]-4-methylpiperidin-4-amine Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2N1CCC(C)(N)CC1 STQJFFXSEGCSLZ-UHFFFAOYSA-N 0.000 description 1
- YABHVDMIMAVUPN-UHFFFAOYSA-N 1-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]piperidin-4-amine Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2N1CCC(N)CC1 YABHVDMIMAVUPN-UHFFFAOYSA-N 0.000 description 1
- MSWVMWGCNZQPIA-UHFFFAOYSA-N 1-fluoropropan-2-one Chemical compound CC(=O)CF MSWVMWGCNZQPIA-UHFFFAOYSA-N 0.000 description 1
- MWFLUYFYHANMCM-UHFFFAOYSA-N 2-(2-hydroxyethyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCO)C(=O)C2=C1 MWFLUYFYHANMCM-UHFFFAOYSA-N 0.000 description 1
- XUEFCTAFIGBGDS-UHFFFAOYSA-N 2-[2-[3-(8-pyrrolidin-1-ylquinolin-2-yl)imidazo[1,2-a]pyridin-7-yl]oxyethyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCOC(=CC1=NC=2)C=CN1C=2C(N=C12)=CC=C1C=CC=C2N1CCCC1 XUEFCTAFIGBGDS-UHFFFAOYSA-N 0.000 description 1
- XRVTYCBVDPVNRI-UHFFFAOYSA-N 2-[3-(8-pyrrolidin-1-ylquinolin-2-yl)imidazo[1,2-a]pyridin-7-yl]oxyethanamine Chemical compound C=1N=C2C=C(OCCN)C=CN2C=1C(N=C12)=CC=C1C=CC=C2N1CCCC1 XRVTYCBVDPVNRI-UHFFFAOYSA-N 0.000 description 1
- PXTSNPRXCQQAGI-UHFFFAOYSA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-8-phenylmethoxyquinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2OCC1=CC=CC=C1 PXTSNPRXCQQAGI-UHFFFAOYSA-N 0.000 description 1
- GEEAYLFEIFJFGP-UHFFFAOYSA-N 2-aminopyridine-4-carbonitrile Chemical compound NC1=CC(C#N)=CC=N1 GEEAYLFEIFJFGP-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 1
- PEWJURPYVYOJQP-UHFFFAOYSA-N 3-(8-bromoquinolin-2-yl)-n,n-dimethylimidazo[1,2-a]pyridine-7-carboxamide Chemical compound C1=CC=C(Br)C2=NC(C=3N4C=CC(=CC4=NC=3)C(=O)N(C)C)=CC=C21 PEWJURPYVYOJQP-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- LGQOGLGFGMBYEU-UHFFFAOYSA-N 3-bromo-5-fluoro-2-methylquinoline Chemical compound C1=CC(F)=C2C=C(Br)C(C)=NC2=C1 LGQOGLGFGMBYEU-UHFFFAOYSA-N 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 1
- QRMIGBOGEJKMQV-UHFFFAOYSA-N 4-ethenyl-8-methoxy-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound C1=CC=C(OC)C2=NC(C=3N4C=CC(=CC4=NC=3)OCCOC)=CC(C=C)=C21 QRMIGBOGEJKMQV-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 1
- UVLKYNJCBYBJRS-UHFFFAOYSA-N 5-(2-methoxyethoxy)pyridin-2-amine Chemical compound COCCOC1=CC=C(N)N=C1 UVLKYNJCBYBJRS-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- AZDWSVWOEDWZSN-UHFFFAOYSA-N 7-pyridin-2-ylimidazo[1,2-a]pyridine Chemical compound C=1C2=NC=CN2C=CC=1C1=CC=CC=N1 AZDWSVWOEDWZSN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- ORVKIFOYWJQPQQ-UHFFFAOYSA-N 8-(3,3-dimethylpiperazin-1-yl)-6-fluoro-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=C(F)C=C2N1CCNC(C)(C)C1 ORVKIFOYWJQPQQ-UHFFFAOYSA-N 0.000 description 1
- DOMWLEPAGKCBBR-UHFFFAOYSA-N 8-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]-1,4-dioxa-8-azaspiro[4.5]decane Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2N(CC1)CCC21OCCO2 DOMWLEPAGKCBBR-UHFFFAOYSA-N 0.000 description 1
- CAJIAUQJSMUVHH-UHFFFAOYSA-N 8-bromo-2-(2-methoxyethenyl)-6-(trifluoromethyl)quinoline Chemical compound C1=C(C(F)(F)F)C=C(Br)C2=NC(C=COC)=CC=C21 CAJIAUQJSMUVHH-UHFFFAOYSA-N 0.000 description 1
- UCXYVGAAZZUQOU-UHFFFAOYSA-N 8-methoxy-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinoline-4-carbaldehyde Chemical compound C1=CC=C(OC)C2=NC(C=3N4C=CC(=CC4=NC=3)OCCOC)=CC(C=O)=C21 UCXYVGAAZZUQOU-UHFFFAOYSA-N 0.000 description 1
- DNMMIDJMOWVQHR-UHFFFAOYSA-N 8-phenylmethoxy-1h-quinolin-2-one Chemical compound C=12NC(=O)C=CC2=CC=CC=1OCC1=CC=CC=C1 DNMMIDJMOWVQHR-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 239000012116 Alexa Fluor 680 Substances 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010048396 Bone marrow transplant rejection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 101150018425 Cr1l gene Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101001001649 Danio rerio Serine/threonine-protein kinase pim-2 Proteins 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 102000054300 EC 2.7.11.- Human genes 0.000 description 1
- 108700035490 EC 2.7.11.- Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101150072536 Flt3 gene Proteins 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000009388 Job Syndrome Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SMRVATNCPGDZHP-UHFFFAOYSA-N N-bromo-4-(trifluoromethyl)aniline Chemical compound BrNC1=CC=C(C=C1)C(F)(F)F SMRVATNCPGDZHP-UHFFFAOYSA-N 0.000 description 1
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101100450580 Nostoc sp. (strain PCC 7120 / SAG 25.82 / UTEX 2576) hepA gene Proteins 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- FNYXIJHFYDRWAX-UHFFFAOYSA-N [2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-4-(1,3-oxazol-5-yl)quinolin-8-yl] trifluoromethanesulfonate Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C1C(OS(=O)(=O)C(F)(F)F)=CC=CC1=1)=CC=1C1=CN=CO1 FNYXIJHFYDRWAX-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000006241 alcohol protecting group Chemical group 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- UQUPQEUNHVVNKW-UHFFFAOYSA-N azetidin-1-ium-3-ol;chloride Chemical compound Cl.OC1CNC1 UQUPQEUNHVVNKW-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- LKGMGCSFOUSKCR-UHFFFAOYSA-N benzyl 2-oxopiperidine-1-carboxylate Chemical compound C1CCCC(=O)N1C(=O)OCC1=CC=CC=C1 LKGMGCSFOUSKCR-UHFFFAOYSA-N 0.000 description 1
- MRSBPLMYLLOCIF-UHFFFAOYSA-N benzyl 4-(2-methoxyethylamino)piperidine-1-carboxylate Chemical compound C1CC(NCCOC)CCN1C(=O)OCC1=CC=CC=C1 MRSBPLMYLLOCIF-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- WOLOGWYRBQNXRP-WBVHZDCISA-N benzyl n-[(3r,4s)-1-(2-amino-4-fluorophenyl)-3-fluoropiperidin-4-yl]carbamate Chemical compound NC1=CC(F)=CC=C1N1C[C@@H](F)[C@@H](NC(=O)OCC=2C=CC=CC=2)CC1 WOLOGWYRBQNXRP-WBVHZDCISA-N 0.000 description 1
- WELKOUYHIUVTPJ-FTJBHMTQSA-N benzyl n-[(3r,4s)-3-fluoro-1-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]piperidin-4-yl]carbamate Chemical compound N([C@H]1CCN(C[C@H]1F)C1=CC=CC2=CC=C(N=C21)C=1N2C=CC(=CC2=NC=1)OCCOC)C(=O)OCC1=CC=CC=C1 WELKOUYHIUVTPJ-FTJBHMTQSA-N 0.000 description 1
- YXAWVLBQAXCPND-UHFFFAOYSA-N benzyl n-[1-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]-4-methylpiperidin-4-yl]carbamate Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2N(CC1)CCC1(C)NC(=O)OCC1=CC=CC=C1 YXAWVLBQAXCPND-UHFFFAOYSA-N 0.000 description 1
- PJVFXCHNQHAGOD-UHFFFAOYSA-N benzyl n-[1-[5-fluoro-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]-4-methylpiperidin-4-yl]carbamate Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C(F)=CC=C2N(CC1)CCC1(C)NC(=O)OCC1=CC=CC=C1 PJVFXCHNQHAGOD-UHFFFAOYSA-N 0.000 description 1
- WRODHPXMZLPBKK-UHFFFAOYSA-N benzyl n-[1-[6-fluoro-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]-4-methylpiperidin-4-yl]carbamate Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=C(F)C=C2N(CC1)CCC1(C)NC(=O)OCC1=CC=CC=C1 WRODHPXMZLPBKK-UHFFFAOYSA-N 0.000 description 1
- BIULEOWAVJTMIG-UHFFFAOYSA-N benzyl n-[4-(hydroxymethyl)piperidin-4-yl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1(CO)CCNCC1.C=1C=CC=CC=1COC(=O)NC1(CO)CCNCC1 BIULEOWAVJTMIG-UHFFFAOYSA-N 0.000 description 1
- VNUIBEJUNBYLKN-UHFFFAOYSA-N benzyl n-[4-(hydroxymethyl)piperidin-4-yl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1(CO)CCNCC1 VNUIBEJUNBYLKN-UHFFFAOYSA-N 0.000 description 1
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZRSDQBKGDNPFLT-UHFFFAOYSA-N ethanol;oxolane Chemical compound CCO.C1CCOC1 ZRSDQBKGDNPFLT-UHFFFAOYSA-N 0.000 description 1
- LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 description 1
- GFVJRPGBYSFNTN-UHFFFAOYSA-N ethyl 1-benzyl-5,5-difluoro-4-oxopiperidine-3-carboxylate Chemical compound C1C(F)(F)C(=O)C(C(=O)OCC)CN1CC1=CC=CC=C1 GFVJRPGBYSFNTN-UHFFFAOYSA-N 0.000 description 1
- DWXKSCKBUSAOKS-UHFFFAOYSA-N ethyl 2-chloro-3-oxopropanoate Chemical compound CCOC(=O)C(Cl)C=O DWXKSCKBUSAOKS-UHFFFAOYSA-N 0.000 description 1
- IFTVTQUKSWTAFW-UHFFFAOYSA-N ethyl 7-(2-methoxyethoxy)imidazo[1,2-a]pyridine-3-carboxylate Chemical compound C1=C(OCCOC)C=CN2C(C(=O)OCC)=CN=C21 IFTVTQUKSWTAFW-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 206010051040 hyper-IgE syndrome Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- SVWWNEYBEFASMP-UHFFFAOYSA-N methyl 2-aminopyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(N)=C1 SVWWNEYBEFASMP-UHFFFAOYSA-N 0.000 description 1
- DOTDPBGGDHABBG-UHFFFAOYSA-N methyl 3-(8-bromoquinolin-2-yl)imidazo[1,2-a]pyridine-7-carboxylate Chemical compound C1=CC=C(Br)C2=NC(C=3N4C=CC(=CC4=NC=3)C(=O)OC)=CC=C21 DOTDPBGGDHABBG-UHFFFAOYSA-N 0.000 description 1
- GICIIASTANSZOT-UHFFFAOYSA-N methyl 3-[8-[4-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-1-yl]quinolin-2-yl]imidazo[1,2-a]pyridine-7-carboxylate Chemical compound C=1N=C2C=C(C(=O)OC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2N1CCC(NC(=O)OC(C)(C)C)CC1 GICIIASTANSZOT-UHFFFAOYSA-N 0.000 description 1
- SCDXZWQMCDSDCA-UHFFFAOYSA-N methyl 4-(phenylmethoxycarbonylamino)piperidine-4-carboxylate Chemical compound C=1C=CC=CC=1COC(=O)NC1(C(=O)OC)CCNCC1 SCDXZWQMCDSDCA-UHFFFAOYSA-N 0.000 description 1
- KYHRVKMXYXBEQN-UHFFFAOYSA-N methyl imidazo[1,2-a]pyridine-7-carboxylate Chemical compound C1=C(C(=O)OC)C=CN2C=CN=C21 KYHRVKMXYXBEQN-UHFFFAOYSA-N 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- NTBNMXKRPHYWFJ-UHFFFAOYSA-N n-(2-methoxyethyl)piperidin-4-amine Chemical compound COCCNC1CCNCC1 NTBNMXKRPHYWFJ-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- AKCMRHXFFCFEKK-UHFFFAOYSA-N n-benzyl-3,3-difluoro-1-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]piperidin-4-amine Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2N(CC1(F)F)CCC1NCC1=CC=CC=C1 AKCMRHXFFCFEKK-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- QAJOLLVGOSCKGP-UHFFFAOYSA-N n-methylpiperidine-4-carboxamide Chemical compound CNC(=O)C1CCNCC1 QAJOLLVGOSCKGP-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-M nicotinate Chemical compound [O-]C(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-M 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108010083755 proto-oncogene proteins pim Proteins 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 1
- YUWOECMFUBVGSE-UHFFFAOYSA-N quinolin-8-yl trifluoromethanesulfonate Chemical compound C1=CN=C2C(OS(=O)(=O)C(F)(F)F)=CC=CC2=C1 YUWOECMFUBVGSE-UHFFFAOYSA-N 0.000 description 1
- ZXZKYYHTWHJHFT-UHFFFAOYSA-N quinoline-2,8-diol Chemical compound C1=CC(=O)NC2=C1C=CC=C2O ZXZKYYHTWHJHFT-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- YKLJDMCXKMIXBD-UHFFFAOYSA-M sodium;3-(2-dicyclohexylphosphanylphenyl)-2,4-dimethoxybenzenesulfonate Chemical compound [Na+].COC1=CC=C(S([O-])(=O)=O)C(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 YKLJDMCXKMIXBD-UHFFFAOYSA-M 0.000 description 1
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- DUOWOUTVIPTSKH-CABCVRRESA-N tert-butyl (3r,4s)-3-fluoro-4-(phenylmethoxycarbonylamino)piperidine-1-carboxylate Chemical compound F[C@@H]1CN(C(=O)OC(C)(C)C)CC[C@@H]1NC(=O)OCC1=CC=CC=C1 DUOWOUTVIPTSKH-CABCVRRESA-N 0.000 description 1
- JXBLMDWEOQDVAC-CABCVRRESA-N tert-butyl (3r,4s)-4-(benzylamino)-3-fluoropiperidine-1-carboxylate Chemical compound F[C@@H]1CN(C(=O)OC(C)(C)C)CC[C@@H]1NCC1=CC=CC=C1 JXBLMDWEOQDVAC-CABCVRRESA-N 0.000 description 1
- ZQRYPCAUVKVMLZ-SFYZADRCSA-N tert-butyl (3r,4s)-4-amino-3-fluoropiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H](N)[C@H](F)C1 ZQRYPCAUVKVMLZ-SFYZADRCSA-N 0.000 description 1
- DHHKPEUQJIEKOA-UHFFFAOYSA-N tert-butyl 2-[6-(nitromethyl)-6-bicyclo[3.2.0]hept-3-enyl]acetate Chemical class C1C=CC2C(CC(=O)OC(C)(C)C)(C[N+]([O-])=O)CC21 DHHKPEUQJIEKOA-UHFFFAOYSA-N 0.000 description 1
- WQBMVRTXKYXMKT-UHFFFAOYSA-N tert-butyl 3,3-difluoro-4,4-dihydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)(O)C(F)(F)C1 WQBMVRTXKYXMKT-UHFFFAOYSA-N 0.000 description 1
- ZTMJHPULXULBFM-UHFFFAOYSA-N tert-butyl 4-(benzylamino)-3,3-difluoropiperidine-1-carboxylate Chemical compound FC1(F)CN(C(=O)OC(C)(C)C)CCC1NCC1=CC=CC=C1 ZTMJHPULXULBFM-UHFFFAOYSA-N 0.000 description 1
- USCZMHLECBLPPD-UHFFFAOYSA-N tert-butyl 4-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]-2,2-dimethylpiperazine-1-carboxylate Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2N1CCN(C(=O)OC(C)(C)C)C(C)(C)C1 USCZMHLECBLPPD-UHFFFAOYSA-N 0.000 description 1
- XEZSCKXSAIFPAD-UHFFFAOYSA-N tert-butyl 4-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]piperazine-1-carboxylate Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2N1CCN(C(=O)OC(C)(C)C)CC1 XEZSCKXSAIFPAD-UHFFFAOYSA-N 0.000 description 1
- SSVAIVLVDFIXMM-UHFFFAOYSA-N tert-butyl 4-[5-fluoro-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]-2,2-dimethylpiperazine-1-carboxylate Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C(F)=CC=C2N1CCN(C(=O)OC(C)(C)C)C(C)(C)C1 SSVAIVLVDFIXMM-UHFFFAOYSA-N 0.000 description 1
- SAOQAHPRZCCSTJ-UHFFFAOYSA-N tert-butyl 4-[6-fluoro-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]-2,2-dimethylpiperazine-1-carboxylate Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=C(F)C=C2N1CCN(C(=O)OC(C)(C)C)C(C)(C)C1 SAOQAHPRZCCSTJ-UHFFFAOYSA-N 0.000 description 1
- QZVYQNHTMJZPLS-UHFFFAOYSA-N tert-butyl n-(2-iodo-6-methoxyphenyl)carbamate Chemical compound COC1=CC=CC(I)=C1NC(=O)OC(C)(C)C QZVYQNHTMJZPLS-UHFFFAOYSA-N 0.000 description 1
- DHSWMVURURVRDB-UHFFFAOYSA-N tert-butyl n-(2-methoxyphenyl)carbamate Chemical compound COC1=CC=CC=C1NC(=O)OC(C)(C)C DHSWMVURURVRDB-UHFFFAOYSA-N 0.000 description 1
- VDQMWAAIGRWIGJ-HZPDHXFCSA-N tert-butyl n-[(3r,4r)-3-fluoro-1-(5-fluoro-2-methylquinolin-8-yl)piperidin-4-yl]carbamate Chemical compound C12=NC(C)=CC=C2C(F)=CC=C1N1CC[C@@H](NC(=O)OC(C)(C)C)[C@H](F)C1 VDQMWAAIGRWIGJ-HZPDHXFCSA-N 0.000 description 1
- OAJHHZOPBGGGSM-UHFFFAOYSA-N tert-butyl n-[1-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-6-(trifluoromethyl)quinolin-8-yl]piperidin-4-yl]carbamate Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=C(C(F)(F)F)C=C2N1CCC(NC(=O)OC(C)(C)C)CC1 OAJHHZOPBGGGSM-UHFFFAOYSA-N 0.000 description 1
- IYJNYSQLKKOOBC-UHFFFAOYSA-N tert-butyl n-[2-methoxy-6-(2-trimethylsilylethynyl)phenyl]carbamate Chemical compound COC1=CC=CC(C#C[Si](C)(C)C)=C1NC(=O)OC(C)(C)C IYJNYSQLKKOOBC-UHFFFAOYSA-N 0.000 description 1
- RWPNJSUSYUZBDY-UHFFFAOYSA-N tert-butyl n-[2-methoxy-6-[3-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-3-oxoprop-1-ynyl]phenyl]carbamate Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(=O)C#CC1=CC=CC(OC)=C1NC(=O)OC(C)(C)C RWPNJSUSYUZBDY-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 1
- GYUURHMITDQTRU-UHFFFAOYSA-N tributyl(pyridin-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CC=N1 GYUURHMITDQTRU-UHFFFAOYSA-N 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- DLQYXUGCCKQSRJ-UHFFFAOYSA-N tris(furan-2-yl)phosphane Chemical compound C1=COC(P(C=2OC=CC=2)C=2OC=CC=2)=C1 DLQYXUGCCKQSRJ-UHFFFAOYSA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90855607P | 2007-03-28 | 2007-03-28 | |
| US60/908,556 | 2007-03-28 | ||
| PCT/US2008/058385 WO2008121687A2 (en) | 2007-03-28 | 2008-03-27 | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2682231A1 true CA2682231A1 (en) | 2008-10-09 |
Family
ID=39731287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002682231A Abandoned CA2682231A1 (en) | 2007-03-28 | 2008-03-27 | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100144751A1 (Direct) |
| EP (1) | EP2139888A2 (Direct) |
| JP (1) | JP2010522765A (Direct) |
| CN (1) | CN101679422A (Direct) |
| CA (1) | CA2682231A1 (Direct) |
| TW (1) | TW200843757A (Direct) |
| WO (1) | WO2008121687A2 (Direct) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ580327A (en) * | 2007-04-03 | 2012-02-24 | Array Biopharma Inc | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
| EP2225252B1 (en) | 2007-11-30 | 2012-06-27 | Novartis AG | C2-c5-alkyl-imidazole-bisphosphonates |
| US8987251B2 (en) | 2008-08-19 | 2015-03-24 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
| WO2010022081A1 (en) | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
| US8895550B2 (en) | 2008-08-19 | 2014-11-25 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
| TWI496779B (zh) * | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物 |
| JP5781943B2 (ja) | 2009-01-21 | 2015-09-24 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 炎症性疾患、自己免疫疾患または増殖性疾患の治療に有用なｎ２−（３−ピリジルまたはフェニル）−ｎ４−（４−ピペリジル）−２，４−ピリミジンジアミン誘導体 |
| AU2010255422B2 (en) | 2009-06-05 | 2014-04-10 | Pfizer Inc. | 1- ( piperidin-4-yl) -pyrazole derivatives as GPR 119 modulators |
| AU2010311511B2 (en) | 2009-10-30 | 2014-07-17 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors |
| EP2332917B1 (en) * | 2009-11-11 | 2012-08-01 | Sygnis Bioscience GmbH & Co. KG | Compounds for PIM kinase inhibition and for treating malignancy |
| FR2952934B1 (fr) * | 2009-11-23 | 2012-06-22 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| US9187435B2 (en) | 2010-11-17 | 2015-11-17 | Actelion Pharmaceuticals Ltd. | Bridged Spiro[2.4]heptane ester derivatives |
| HRP20160134T1 (hr) * | 2011-02-25 | 2016-04-08 | Array Biopharma, Inc. | Spojevi triazolopiridina kao inhibitori pim kinaze |
| EP2524915A1 (en) | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
| MX344600B (es) | 2011-06-27 | 2016-12-20 | Janssen Pharmaceutica Nv | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina. |
| WO2013005057A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | New compounds |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| ES2586527T3 (es) | 2011-10-14 | 2016-10-17 | Ambit Biosciences Corporation | Compuestos heterocíclicos y uso de los mismos como moduladores del receptor de tirosina quinasas de tipo III |
| MA37618B1 (fr) | 2012-05-16 | 2017-08-31 | Actelion Pharmaceuticals Ltd | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
| AU2013283426B2 (en) | 2012-06-26 | 2018-02-22 | Janssen Pharmaceutica Nv | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| CN104411314B (zh) | 2012-07-09 | 2017-10-20 | 詹森药业有限公司 | 磷酸二酯酶10的抑制剂 |
| CA2886187C (en) * | 2012-09-28 | 2020-04-14 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| ES2941292T3 (es) | 2013-01-15 | 2023-05-19 | Incyte Holdings Corp | Tiazolecarboxamidas y compuestos de piridinecarboxamida útiles como inhibidores de PIM quinasa |
| AR097431A1 (es) | 2013-08-23 | 2016-03-16 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| CN104597194B (zh) * | 2015-01-15 | 2016-07-06 | 武汉轻工大学 | 3-氯-1，2-丙二醇的高效液相色谱-荧光检测方法 |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| SG11202002032SA (en) | 2017-09-22 | 2020-04-29 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
| AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| KR20200085836A (ko) | 2017-11-06 | 2020-07-15 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체 |
| AU2018372211B2 (en) | 2017-11-24 | 2023-02-02 | Jubilant Episcribe LLC, | Heterocyclic compounds as PRMT5 inhibitors |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| AU2019234185B2 (en) | 2018-03-13 | 2024-08-01 | Jubilant Prodel LLC. | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
| US10745400B2 (en) | 2018-03-14 | 2020-08-18 | Vanderbuilt University | Inhibition of BMP signaling, compounds, compositions and uses thereof |
| CN110833556A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗肝纤维化的用途 |
| US20240025892A1 (en) * | 2020-08-05 | 2024-01-25 | The General Hospital Corporation | Salt inducible kinase inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| ATE381332T1 (de) * | 2002-05-02 | 2008-01-15 | Merck & Co Inc | Tyrosinkinase-hemmer |
| AU2004264419B2 (en) * | 2003-08-15 | 2009-01-15 | Irm Llc | 6-substituted anilino purines as RTK inhibitors |
| US20050256309A1 (en) * | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands |
-
2008
- 2008-03-27 CA CA002682231A patent/CA2682231A1/en not_active Abandoned
- 2008-03-27 CN CN200880017972A patent/CN101679422A/zh active Pending
- 2008-03-27 WO PCT/US2008/058385 patent/WO2008121687A2/en not_active Ceased
- 2008-03-27 EP EP08732914A patent/EP2139888A2/en not_active Withdrawn
- 2008-03-27 JP JP2010501214A patent/JP2010522765A/ja active Pending
- 2008-03-27 US US12/593,041 patent/US20100144751A1/en not_active Abandoned
- 2008-03-28 TW TW097111546A patent/TW200843757A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200843757A (en) | 2008-11-16 |
| WO2008121687A2 (en) | 2008-10-09 |
| EP2139888A2 (en) | 2010-01-06 |
| WO2008121687A3 (en) | 2008-11-20 |
| JP2010522765A (ja) | 2010-07-08 |
| CN101679422A (zh) | 2010-03-24 |
| US20100144751A1 (en) | 2010-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2682231A1 (en) | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors | |
| CA2682981C (en) | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors | |
| CN104520290B (zh) | 酰氨基螺环酰胺和磺酰胺衍生物 | |
| AU2012254082B2 (en) | Triazolopyridine compounds as PIM kinase inhibitors | |
| US20230226062A1 (en) | Heterocyclic compounds as immunomodulators | |
| CA2734831A1 (en) | Triazolopyridine compounds as pim kinase inhibitors | |
| KR20080026654A (ko) | 헤테로시클릭 야누스 키나제 3 억제제 | |
| HK1140200B (en) | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20140327 |